<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05056207</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0639</org_study_id>
    <nct_id>NCT05056207</nct_id>
  </id_info>
  <brief_title>PREVENT: PeRomEter Visualization to ENd Treatment-related Lymphedema</brief_title>
  <official_title>PREVENT: PeRomEter Visualization to ENd Treatment-related Lymphedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is to learn about breast cancer patients' opinions about screening for&#xD;
      lymphedema (a side effect of breast cancer treatment in which the arm can become heavy,&#xD;
      painful, and/or swollen) and their satisfaction with the lymphedema screening program.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        -  To determine the effectiveness of prospective, intensive lymphedema screening in the&#xD;
           postoperative setting using a perometer for reducing the cumulative incidence of grade&#xD;
           lymphedema among breast cancer patients after ALND compared to routine screening.&#xD;
           Secondary Objectives:&#xD;
&#xD;
        -  To estimate the direct costs associated with the Lymphedema Screening Initiative&#xD;
&#xD;
        -  To determine the association of the Initiative on patient productivity&#xD;
&#xD;
        -  To determine patient satisfaction with the Lymphedema Initiative in the context of their&#xD;
           cancer care&#xD;
&#xD;
        -  To determine patient understanding of lymphedema-associated symptoms&#xD;
&#xD;
        -  To determine patient self-reported compliance with treatments and measures to prevent&#xD;
           lymphedema&#xD;
&#xD;
        -  To determine the incidence of breast cancer-related lymphedema among a cohort of breast&#xD;
           cancer patients treated with ALND To analyze clinical and pathological features&#xD;
           associated with the development of lymphedema&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 17, 2017</start_date>
  <completion_date type="Anticipated">November 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 17, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the effectiveness of prospective, intensive lymphedema screening in the postoperative setting using a perometer.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">558</enrollment>
  <condition>Lymphedema</condition>
  <arm_group>
    <arm_group_label>Cohort I (patients receiving annual lymphedema screening)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>We will retrospectively retrieve information on patients who previously underwent preoperative perometer lymphedema screening during the past year who were treated definitively for their breast cancer with an ALND, and for whom no follow-up postoperative lymphedema screening was done.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort II (patients followed intensively for lymphedema)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>We will prospectively follow a cohort of 279 patients who have recently undergone ALND in this upcoming year with intensive lymphedema screening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cohort I (patients receiving annual lymphedema screening</intervention_name>
    <description>patientns who previously underwent preoperative perometer lymphedema screening</description>
    <arm_group_label>Cohort I (patients receiving annual lymphedema screening)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cohort II (patients followed intensively for lymphedema)</intervention_name>
    <description>patients who have recently undergone ALND</description>
    <arm_group_label>Cohort II (patients followed intensively for lymphedema)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        a Cohort A:&#xD;
&#xD;
          -  Breast cancer patients with a baseline (preoperative perometer measurements) who have&#xD;
             undergone axillary lymph node dissection&#xD;
&#xD;
          -  English speaker&#xD;
&#xD;
          -  Patients who participate in Cohort A will be eligible for enrollment in Cohort&#xD;
&#xD;
        b Cohort I:&#xD;
&#xD;
          -  Breast cancer patients who have undergone axillary lymph node dissection who have a&#xD;
             clinic visit in the Nellie B. Connally Breast Center approximately 12 months (+/- 4&#xD;
             months) following axillary lymph node dissection&#xD;
&#xD;
          -  English speaker&#xD;
&#xD;
        c Cohort II:&#xD;
&#xD;
          -  Breast cancer patients who have undergone axillary lymph node dissection who are&#xD;
             having a follow-up visit in the Nellie B. Connally Breast Center within 0-6 months&#xD;
             following surgery who intend to continue follow-up care at MD Anderson&#xD;
&#xD;
          -  English speaker&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Inability to complete a self-administered questionnaire&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simona Shaitelman</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

